Antineoplastic Agents, Immunological

Name
Antineoplastic Agents, Immunological
Accession Number
DBCAT004966
Description

Monoclonal antibodies that inhibit or prevent the proliferation of NEOPLASMS.

Drugs
DrugDrug Description
CetuximabAn endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.
TrastuzumabA monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.
AlemtuzumabA monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.
BevacizumabA monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
PanitumumabA recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
EpratuzumabInvestigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
OregovomabInvestigated for use/treatment in ovarian cancer.
LabetuzumabLabetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab"
BavituximabInvestigated for use/treatment in breast cancer, cancer/tumors (unspecified), HIV infection, hepatitis (viral, C), and solid tumors.
RindopepimutInvestigated for use/treatment in brain cancer.
Trastuzumab emtansineAn antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer.
CT-011Investigated for use/treatment in cancer/tumors (unspecified).
Glembatumumab vedotinInvestigated for use/treatment in melanoma.
IpilimumabA human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
NimotuzumabAn EGFR-targeting monoclonal antibody used in the treatment of squamous cell carcinomas of the head and neck and glioblastomas.
PertuzumabAn antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents.
ObinutuzumabAn antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.
NivolumabA PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
PembrolizumabA PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
NecitumumabA monoclonal antibody used to treat metastatic squamous non-small cell lung cancer.
ConatumumabConatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others.
DurvalumabAn antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer.
RilotumumabRilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others.
ZalutumumabZalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell...
DacetuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma.
IntetumumabIntetumumab has been used in trials studying the treatment of Melanoma.
EcromeximabEcromeximab has been used in trials studying the treatment of Cutaneous Melanoma and Metastatic Melanoma.
Talimogene laherparepvecA genetically modified virus used to treat recurrent melanoma, or metastatic melanoma.
CemiplimabA programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.
LintuzumabLintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
PidilizumabPidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma).
AbagovomabAbagovomab is under investigation in clinical trial NCT00418574 (Efficacy Multicentre Trial of Immunotherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients).
MagrolimabMagrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
Tisotumab vedotinA tissue factor-directed antibody drug conjugate that is used to treat adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Brentuximab vedotinA CD30-directed antibody-drug conjugate used to treat various types of lymphoma.
AvelumabA monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
TisagenlecleucelA CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma.
Axicabtagene ciloleucelA CAR T-cell therapy used to treat adults with large B-cell lymphomas and follicular lymphoma.
Idecabtagene vicleucelAn autologous T-cell therapy indicated to treat relapsed or refractory multiple myeloma.
AmivantamabAn EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation.
Gemtuzumab ozogamicinA monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia.
RituximabA monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.
Inotuzumab ozogamicinAn antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL).
Lorvotuzumab mertansineLorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
TislelizumabTislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
Brexucabtagene autoleucelA modified autologous chimeric antigen receptor (CAR) T cell therapy employing a modified murine anti-CD19 single-chain variable fragment linked to CD28 and CD3ΞΆ co-stimulatory domains for the treatment of patients with relapsed and refractory mantle cell lymphoma.
BemarituzumabBemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)).
Loncastuximab tesirineAn antibody-drug conjugate used for the treatment of relapsed and refractory B-cell lymphomas.
AbataceptA disease-modifying antirheumatic drug (DMARD) used in the management of rheumatic conditions, such as rheumatoid or psoriatic arthritis, and for the prophylaxis of acute graft-versus-host disease.
BelataceptA selective T-cell costimulation blocker used in the prophylaxis of organ rejection in adult patients receiving a kidney transplant.
SpartalizumabSpartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).
SotorasibAn experimental KRAS inhibitor being investigated for the treatment of KRAS G12C mutant non small cell lung cancer, colorectal cancer, and appendix cancer.
Cantuzumab mertansineNot Annotated
BI 836826Not Annotated
ZanolimumabZanolimumab is a fully human monoclonal antibody directed against CD4.
AdagrasibA KRAS inhibitor indicated for the treatment of locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer in patients who have received at least one prior systemic therapy.
Drugs & Drug Targets
DrugTargetType
CetuximabEpidermal growth factor receptortarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
CetuximabComplement C1q subcomponent subunit Atarget
CetuximabComplement C1q subcomponent subunit Btarget
CetuximabComplement C1q subcomponent subunit Ctarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
CetuximabHigh affinity immunoglobulin gamma Fc receptor Itarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
TrastuzumabReceptor tyrosine-protein kinase erbB-2target
AlemtuzumabCAMPATH-1 antigentarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
BevacizumabVascular endothelial growth factor Atarget
BevacizumabComplement C1q subcomponent subunit Atarget
BevacizumabComplement C1q subcomponent subunit Btarget
BevacizumabComplement C1q subcomponent subunit Ctarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
PanitumumabEpidermal growth factor receptortarget
EpratuzumabB-cell receptor CD22target
OregovomabMucin-16target
LabetuzumabCarcinoembryonic antigen-related cell adhesion molecule 5target
RindopepimutEpidermal growth factor receptortarget
Trastuzumab emtansineReceptor tyrosine-protein kinase erbB-2target
Trastuzumab emtansineP-glycoprotein 1transporter
Trastuzumab emtansineCytochrome P450 3A4enzyme
Trastuzumab emtansineCytochrome P450 3A5enzyme
CT-011Programmed cell death protein 1target
Glembatumumab vedotinTransmembrane glycoprotein NMBtarget
IpilimumabCytotoxic T-lymphocyte protein 4target
PertuzumabReceptor tyrosine-protein kinase erbB-2target
ObinutuzumabB-lymphocyte antigen CD20target
NivolumabProgrammed cell death protein 1target
NivolumabProgrammed cell death 1 ligand 1target
PembrolizumabProgrammed cell death protein 1target
PembrolizumabProgrammed cell death 1 ligand 1target
NecitumumabEpidermal growth factor receptortarget
DurvalumabProgrammed cell death 1 ligand 1target
DurvalumabProgrammed cell death protein 1target
ZalutumumabEpidermal growth factor receptortarget
DacetuzumabTumor necrosis factor receptor superfamily member 5target
Talimogene laherparepvecHeparan sulfatetarget
Talimogene laherparepvecDNA polymerase catalytic subunittarget
Talimogene laherparepvecDNA polymerase catalytic subunittarget
CemiplimabProgrammed cell death protein 1target
Tisotumab vedotinCytochrome P450 3A4enzyme
Tisotumab vedotinTissue factortarget
Tisotumab vedotinP-glycoprotein 1transporter
Brentuximab vedotinTumor necrosis factor receptor superfamily member 8target
Brentuximab vedotinCytochrome P450 3A4enzyme
Brentuximab vedotinATP-binding cassette sub-family B member 5transporter
AvelumabProgrammed cell death 1 ligand 1target
AvelumabProgrammed cell death protein 1target
TisagenlecleucelB-lymphocyte antigen CD19target
Axicabtagene ciloleucelB-lymphocyte antigen CD19target
Idecabtagene vicleucelTumor necrosis factor receptor superfamily member 17target
AmivantamabEpidermal growth factor receptortarget
AmivantamabHepatocyte growth factor receptortarget
AmivantamabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
Gemtuzumab ozogamicinMyeloid cell surface antigen CD33target
Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Btarget
Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Atarget
Gemtuzumab ozogamicinHigh affinity immunoglobulin gamma Fc receptor Itarget
RituximabB-lymphocyte antigen CD20target
Inotuzumab ozogamicinP-glycoprotein 1transporter
Inotuzumab ozogamicinB-cell receptor CD22target
Lorvotuzumab mertansineCytochrome P450 3A4enzyme
TislelizumabProgrammed cell death protein 1target
Brexucabtagene autoleucelB-lymphocyte antigen CD19target
Loncastuximab tesirineB-lymphocyte antigen CD19target
Loncastuximab tesirineP-glycoprotein 1transporter
Loncastuximab tesirineCytochrome P450 3A4enzyme
Loncastuximab tesirineCytochrome P450 3A5enzyme
AbataceptT-lymphocyte activation antigen CD80target
AbataceptT-lymphocyte activation antigen CD86target
AbataceptCytotoxic T-lymphocyte protein 4target
BelataceptT-lymphocyte activation antigen CD86target
BelataceptT-lymphocyte activation antigen CD80target
SpartalizumabProgrammed cell death protein 1target
SotorasibGTPase KRastarget
SotorasibCytochrome P450 3A Subfamilyenzyme
SotorasibCytochrome P450 2C8enzyme
SotorasibCytochrome P450 2C9enzyme
SotorasibCytochrome P450 2B6enzyme
SotorasibATP-binding cassette sub-family G member 2transporter
SotorasibP-glycoprotein 1transporter
AdagrasibGTPase KRastarget
AdagrasibCytochrome P450 3A4enzyme
AdagrasibCytochrome P450 2C8enzyme
AdagrasibCytochrome P450 1A2enzyme
AdagrasibCytochrome P450 2B6enzyme
AdagrasibCytochrome P450 2C9enzyme
AdagrasibCytochrome P450 2D6enzyme
AdagrasibP-glycoprotein 1transporter